Acquired Immunodeficiency Syndrome (AIDS) Market Trends Support A 5.1% CAGR Outlook Through The Forecast Period

The acquired immunodeficiency syndrome (AIDS) market is poised for significant growth in the coming years, driven by advancements in treatment and prevention strategies. Innovations in therapies and expanding healthcare initiatives are expected to shape the landscape of this critical healthcare sector. Let's delve into the market's size projections, key players, emerging trends, and important segments defining its trajectory.

Strong Growth Expectations for the Acquired Immunodeficiency Syndrome (AIDS) Market
The AIDS market is forecasted to reach a valuation of $43.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1%. This upward trend is supported by the introduction of next-generation antiretroviral therapies, the broadening reach of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) programs, increasing investments in HIV vaccine research, and the adoption of digital health monitoring platforms. Moreover, enhanced collaboration between public and private sectors to manage HIV contributes significantly to the market's expansion. Noteworthy market trends include the rising acceptance of antiretroviral therapy (ART), growth in preventive measures such as PrEP and PEP, expansion of HIV diagnostics and surveillance, intensified focus on vaccine development, and greater integration of hospital and retail pharmacy services.

The acquired immunodeficiency syndrome (aids) market size has grown strongly in recent years. It will grow from $33.75 billion in 2025 to $35.53 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high prevalence of hiv infections worldwide, increasing awareness and screening programs, government-funded hiv treatment initiatives, availability of first-generation antiretroviral drugs, rising incidence of opportunistic infections.

Download a free sample of the acquired immunodeficiency syndrome (aids) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Key Companies Leading the Acquired Immunodeficiency Syndrome (AIDS) Market
Several prominent pharmaceutical and biotechnology firms play a crucial role in the AIDS market landscape. These include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, and ViiV Healthcare.
In a strategic move in November 2024, Gilead Sciences Inc., based in the US, acquired investigational assets related to the HTI therapeutic HIV vaccine from Spain's AELIX Therapeutics for an undisclosed sum. This acquisition is intended to bolster Gilead's HIV treatment portfolio by advancing research into functional cures for HIV, potentially reducing the lifelong dependency on antiretroviral therapies.

Innovative Treatment Trends Shaping the AIDS Market
The AIDS market is witnessing a growing focus on the development of long-acting injectable therapies. These formulations aim to improve patient adherence by reducing the frequency of dosing, offering a more convenient alternative to the daily oral antiretroviral medications currently in use. Long-acting injectables slowly release medication over an extended period, making treatment regimens less burdensome.
For instance, in January 2025, GSK plc received approval from the European Commission for a long-acting injectable treatment comprising Vocabria (cabotegravir) and Rekambys (rilpivirine). This therapy is approved for adolescents aged 12 and older living with HIV and is administered via intramuscular injection every one or two months depending on treatment plans. This approach holds promise for improving adherence among younger patients who find daily pill routines challenging.

View the full acquired immunodeficiency syndrome (aids) market report:
https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Segmentation Overview of the Acquired Immunodeficiency Syndrome (AIDS) Market
The AIDS market report categorizes the market into various segments to provide a detailed outlook:
1) By Type: Human Immunodeficiency Virus 1 (HIV-1) and Human Immunodeficiency Virus 2 (HIV-2)
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Antagonists and Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis, and Post-Exposure Prophylaxis
3) By Route of Administration: Oral and Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, and Other Applications
5) By Distribution Channel: Offline and Online

Further breakdown includes:
- For HIV-1: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, and Management of HIV-1 Opportunistic Infections.
- For HIV-2: Antiretroviral Therapy specific to HIV-2, Diagnostic Tests, Surveillance and Epidemiology, Vaccine Research, and Management of HIV-2 Co-Infections.

These segments offer a comprehensive view of the market's diverse therapeutic and logistical components, underscoring the complexity and dynamic nature of AIDS treatment and prevention efforts globally.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.